Recent advances in subtyping tumors of the central nervous system using molecular data

References

• Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62.
   PubMed Web of Science ®Google Scholar
• Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48–54.
   PubMed Web of Science ®Google Scholar
• Halani SH. Brat DJ: defining neoplastic diseases differently: an emerging paradigm from The Cancer Genome Atlas lower-grade gliomas project. Mol Cell Oncol. 2016;3(2):e1074333.
   Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–820.
   PubMed Web of Science ®Google Scholar
• Gramatzki D, Dehler S, Rushing EJ, et al. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer. 2016;122(14):2206–2215.
   PubMed Web of Science ®Google Scholar
• Ellis HP, Greenslade M, Powell B, et al. Current challenges in glioblastoma: intratumour heterogeneity, residual disease, and models to predict disease recurrence. Front Oncol. 2015;5:251.
   PubMed Web of Science ®Google Scholar
• Sundar SJ, Hsieh JK, Manjila S, et al. The role of cancer stem cells in glioblastoma. Neurosurg Focus. 2014;37(6):E6.
   PubMed Web of Science ®Google Scholar
• Sahm F, Schrimpf D, Jones DT, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131(6):903–910.
   PubMed Web of Science ®Google Scholar
• Jorgensen JT. The importance of predictive biomarkers in oncology drug development. Expert Rev Mol Diagn. 2016;16(8):807–809.
   PubMed Web of Science ®Google Scholar
• Schittenhelm J, Skardelly M. Molecular advances in glioblastoma neuropathology. In: Amit A, editor. Neurooncology newer developments. ed. Rijeka: Intech; 2016. p. 3–26. doi:10.5772/62670.
   Google Scholar
• Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–772.
   PubMed Web of Science ®Google Scholar
• Unruh D, Schwarze SR, Khoury L, et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol. 2016;132(6):917–930.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773.
   PubMed Web of Science ®Google Scholar
• Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119(4):487–494.
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324–327.
   PubMed Web of Science ®Google Scholar
• van Breemen MS, Rijsman RM, Taphoorn MJ, et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256(9):1519–1526.
   PubMed Web of Science ®Google Scholar
• Koelsche C, Sahm F, Capper D, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013;126(6):907–915.
   PubMed Web of Science ®Google Scholar
• Reuss DE, Kratz A, Sahm F, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 2015;130(3):407–417.
   PubMed Web of Science ®Google Scholar
• Rodriguez FJ, Vizcaino MA. Lin MT: recent advances on the molecular pathology of glial neoplasms in children and adults. J Mol Diagn. 2016;18(5):620–634.
   PubMed Web of Science ®Google Scholar
• Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn. 2016;16(7):737–749.
   PubMed Web of Science ®Google Scholar
• Kim H, Zheng S, Amini SS, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25(3):316–327.
   PubMed Web of Science ®Google Scholar
• Kim J, Lee IH, Cho HJ, et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell. 2015;28(3):318–328.
   PubMed Web of Science ®Google Scholar
• Wang J, Cazzato E, Ladewig E, et al. Clonal evolution of glioblastoma under therapy. Nat Genet. 2016;48(7):768–776.
   PubMed Web of Science ®Google Scholar
• Dupati A, Gill L. Vemurafenib: background, patterns of resistance, and strategies to combat resistance in melanoma. Medical Student Research Journal. 2014;3(Winter):36–43.
   Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466.
   PubMed Web of Science ®Google Scholar
• Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–926.
   PubMed Web of Science ®Google Scholar
• Tanboon J, Williams EA, Louis DN. The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas. J Neuropathol Exp Neurol. 2016;75(1):4–18.
   PubMed Web of Science ®Google Scholar
• Wiestler B, Capper D, Sill M, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014;128(4):561–571.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061–1068. doi:10.1038/nature07385.
   PubMed Web of Science ®Google Scholar
• Ortega A, Nuno M, Walia S, et al. Treatment and survival of patients harboring histological variants of glioblastoma. J Clin Neurosci. 2014;21(10):1709–1713.
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, et al. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013;37(5):685–698.
   PubMed Web of Science ®Google Scholar
• Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469–474.
   PubMed Web of Science ®Google Scholar
• Idbaih A, Ducray F, Dehais C, et al. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. Plos One. 2012;7(10):e45950.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709–722.
   PubMed Web of Science ®Google Scholar
• Ebrahimi A, Skardelly M, Bonzheim I, et al. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun. 2016;4(1):60.
   PubMed Web of Science ®Google Scholar
• Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–343.
   PubMed Web of Science ®Google Scholar
• Grimm SA. Chamberlain MC: anaplastic astrocytoma. CNS Oncol. 2016;5(3):145–157.
   PubMedGoogle Scholar
• Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129(6):867–873.
   PubMed Web of Science ®Google Scholar
• Qaddoumi I, Orisme W, Wen J, et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 2016;131(6):833–845.
   PubMed Web of Science ®Google Scholar
• Krishnatry R, Zhukova N, Guerreiro Stucklin AS, et al. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer. 2016;122(8):1261–1269.
   PubMed Web of Science ®Google Scholar
• Mesturoux L, Durand K, Pommepuy I, et al. Molecular analysis of tumor cell components in pilocytic astrocytomas, gangliogliomas, and oligodendrogliomas. Appl Immunohistochem Mol Morphol. 2016;24(7):496–500.
   PubMedGoogle Scholar
• Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 2009;118(3):401–405.
   PubMed Web of Science ®Google Scholar
• Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res. 2011;17(14):4790–4798.
   PubMed Web of Science ®Google Scholar
• Brokinkel B, Peetz-Dienhart S, Ligges S, et al. A comparative analysis of MAPK pathway hallmark alterations in pilocytic astrocytomas: age-related and mutually exclusive. [Corrected]. Neuropathol Appl Neurobiol. 2015;41(2):258–261.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602–612.
   PubMed Web of Science ®Google Scholar
• Roth JJ, Fierst TM, Waanders AJ, et al. Whole Chromosome 7 Gain Predicts Higher Risk of Recurrence in Pediatric Pilocytic Astrocytomas Independently From KIAA1549-BRAF Fusion Status. J Neuropathol Exp Neurol. 2016;75(4):306–315.
   PubMed Web of Science ®Google Scholar
• Rodriguez FJ, Schniederjan MJ, Nicolaides T, et al. High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). Acta Neuropathol. 2015;129(4):609–610.
   PubMed Web of Science ®Google Scholar
• Chappe C, Padovani L, Scavarda D, et al. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol. 2013;23(5):574–583.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Recurrent ganglioglioma in adults treated with BRAF inhibitors. CNS Oncol. 2016;5(1):27–29.
   PubMedGoogle Scholar
• Worst BC, van Tilburg CM, Balasubramanian GP, et al. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. Eur J Cancer. 1990;2016(65):91–101.
   Google Scholar
• Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425–437.
   PubMed Web of Science ®Google Scholar
• Venneti S, Santi M, Felicella MM. et al. : A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol. 2014;128(5):743–753.
   PubMed Web of Science ®Google Scholar
• Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444–450.
   PubMed Web of Science ®Google Scholar
• Gessi M, Capper D, Sahm F, et al. Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathol. 2016;132(4):635–637.
   PubMed Web of Science ®Google Scholar
• Korshunov A, Capper D, Reuss D, et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol. 2016;131(1):137–146.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–231.
   PubMed Web of Science ®Google Scholar
• Korshunov A, Ryzhova M, Hovestadt V, et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 2015;129(5):669–678.
   PubMed Web of Science ®Google Scholar
• Fruhwald MC, Biegel JA, Bourdeaut F, et al. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro Oncol. 2016;18(6):764–778.
   PubMed Web of Science ®Google Scholar
• Wetmore C, Boyett J, Li S, et al. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Neuro Oncol. 2015;17(6):882–888.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131(6):821–831.
   PubMed Web of Science ®Google Scholar
• Kaur K, Kakkar A, Kumar A, et al. Integrating molecular subclassification of medulloblastomas into routine clinical practice: a simplified approach. Brain Pathol. 2016;26(3):334–343.
   PubMed Web of Science ®Google Scholar
• Rimkus TK, Carpenter RL, Qasem S, et al. Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers. 2016;8:2.
   Web of Science ®Google Scholar
• Morfouace M, Shelat A, Jacus M, et al. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell. 2014;25(4):516–529.
   PubMed Web of Science ®Google Scholar
• Spence T, Sin-Chan P, Picard D. et al. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014;128(2):291–303.
   PubMed Web of Science ®Google Scholar
• Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell. 2016;164(5):1060–1072.
   PubMed Web of Science ®Google Scholar
• Kros JM. Grading of gliomas: the road from eminence to evidence. J Neuropathol Exp Neurol. 2011;70(2):101–109.
   PubMed Web of Science ®Google Scholar
• Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature. 2014;506(7489):451–455.
   PubMed Web of Science ®Google Scholar
• Atkinson JM, Shelat AA, Carcaboso AM, et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell. 2011;20(3):384–399.
   PubMed Web of Science ®Google Scholar
• Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27(5):728–743.
   PubMed Web of Science ®Google Scholar
• Godfraind C, Kaczmarska JM, Kocak M, et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol. 2012;124(2):247–257.
   PubMed Web of Science ®Google Scholar
• Gajjar A, Pfister SM, Taylor MD, et al. Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res. 2014;20(22):5630–5640.
   PubMed Web of Science ®Google Scholar
• Prabowo AS, van Thuijl HF, Scheinin I, et al. Landscape of chromosomal copy number aberrations in gangliogliomas and dysembryoplastic neuroepithelial tumours. Neuropathol Appl Neurobiol. 2015;41(6):743–755.
   PubMed Web of Science ®Google Scholar
• Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397–405.
   PubMed Web of Science ®Google Scholar
• Zanello M, Pages M, Tauziede-Espariat A, et al. Clinical, imaging, histopathological and molecular characterization of anaplastic ganglioglioma. J Neuropathol Exp Neurol. 2016;75(10):971–980.
   PubMed Web of Science ®Google Scholar
• Rivera B, Gayden T, Carrot-Zhang J, et al. Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathol. 2016;131(6):847–863.
   PubMed Web of Science ®Google Scholar